Biodesix (NASDAQ:BDSX) Releases Quarterly Earnings Results

Biodesix (NASDAQ:BDSX) released its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01, Zacks reports. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. Biodesix updated its FY 2025 guidance to EPS.

Biodesix Stock Performance

Biodesix stock traded down $0.08 during trading hours on Monday, reaching $0.71. 406,858 shares of the stock were exchanged, compared to its average volume of 386,054. Biodesix has a 52-week low of $0.70 and a 52-week high of $2.04. The stock has a market cap of $103.72 million, a P/E ratio of -1.83 and a beta of 1.06. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The firm’s 50 day moving average is $1.14 and its 200 day moving average is $1.43.

Insider Activity

In other news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the transaction, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This represents a 10.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 128,702 shares of company stock valued at $118,406 over the last quarter. Corporate insiders own 69.20% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.